E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Phase 1
Terminated
- Conditions
- Brain MetastasesMalignant Melanoma
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Spirita Oncology, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT03332589
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Spirita Oncology, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT02418000
- Locations
- 🇺🇸
Texas Transplant Institute, San Antonio, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸H. Lee Moffitt Cancer Center & research Institute, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath